A Multicenter, Open-Label, Single Arm, Phase II Study of Daratumumab as Consolidation/Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma
Latest Information Update: 18 Aug 2023
At a glance
- Drugs Daratumumab (Primary) ; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- 14 Aug 2023 Status changed from suspended to active, no longer recruiting.
- 19 Jun 2023 Planned End Date changed from 5 Dec 2023 to 17 Jul 2025.
- 19 Jun 2023 Planned primary completion date changed from 5 Dec 2023 to 17 Jul 2025.